| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
| Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How | Sarah de Crescenzo | 07/15/20 | Boston |
| AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis | Frank Vinluan | 06/24/20 | National |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| CEOs of Women’s Health Companies Fight to Open Investment Floodgates | Sarah de Crescenzo | 01/22/20 | San Diego |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive | Sarah de Crescenzo | 01/14/20 | San Diego |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio | Sarah de Crescenzo | 11/15/19 | San Diego |
| Bayer and Dewpoint Ink Deal for Drugs R&D at New Frontier of Biology | Frank Vinluan | 11/14/19 | Boston |
| Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More | Sarah de Crescenzo | 10/25/19 | National |
| Plexium Debuts With $28M and a New Take on Protein Degradation Drugs | Sarah de Crescenzo | 10/17/19 | San Diego |
| High-Flying Ginkgo Nets Another $290M to Program Cells Like Computers | Frank Vinluan | 09/19/19 | Boston |
| Elanco’s $7.6B Deal With Bayer Bolsters Pets, Farm Animals Footprint | Frank Vinluan | 08/20/19 | Indiana |
| Four New Drugs Are Around the Corner. Here’s What You Need to Know. | Ben Fidler | 08/15/19 | National |
| Bio Roundup: Surprise News, a Gene Therapy Mess & a CAR-T Step | Ben Fidler | 08/09/19 | National |
| Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work | Ben Fidler | 08/08/19 | Boston |
| Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More | Frank Vinluan | 08/02/19 | National |
| Joyn Bio Reaches Deal to Tap Into NewLeaf’s Plant Microbe Library | Frank Vinluan | 07/22/19 | Boston |
| Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D | Frank Vinluan | 06/12/19 | Boston |
| Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance | Frank Vinluan | 06/04/19 | Boston |
| Ginkgo Eyes Antibiotics With Deal for Warp Drive’s Gene “Mining” Tech | Frank Vinluan | 05/15/19 | Boston |
